Apparatus

DNA nano robot system is one of the nano machines, and has been continuously developed in recent years. In recent years, in the journal Science, we saw another "feat" realized by DNA nano robot - researchers used electric field to accelerate the movement speed of DNA robot system.

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.

The global ADC drug market will be approximately $5.2 billion by 2021

According to Telegraph, a new study shows that human doctors will still outperform "robot doctors" in surgery. Compared with robots, human doctors need shorter time to complete surgery, and the error rate is not high.

Ibuprofen belongs to antipyretic and analgesic, not cold medicine.

The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.

Stroke is the main cause of disability in Americans. More than 6.5 million Americans survive stroke every year, and most of them cannot fully recover their walking ability. Experts said that because of the difficulty in walking, these patients would not even go out to the store to buy things, but they were inactive for a long time, which led to other health problems and a spiral decline in their quality of life.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."

The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.